



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

18 March 2026
EMA/CAT/64755/2026
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 18-20 March 2026

Chair: Ilona Reischl-Kok; Vice-Chair: Kieran Breen

18 March 2026, 14:00 – 18:30

19 March 2026, 09:00 – 18:30

20 March 2026, 09:00 – 13:00

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.1.1.	Nadofaragene firadenovec - EMEA/H/C/005856	5
2.2.	Oral explanations	5
2.3.	Day 180 list of outstanding issues	5
2.3.1.	Autologous melanoma-derived tumour infiltrating lymphocytes, ex vivo-expanded - EMEA/H/C/006563.....	5
2.4.	Day 120 list of questions	6
2.4.1.	Zopapogene Imadenovec - Orphan - EMEA/H/C/006508.....	6
2.5.	Day 80 assessment reports	6
2.6.	Update on ongoing initial applications.....	6
2.7.	New applications	6
2.8.	Withdrawal of initial marketing authorisation application	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	6
2.10.	GMP and GCP inspections requests.....	6
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	6
2.11.1.	Aucatzyl - Obecabtagene autoleucel - Orphan - EMA/VR/0000322591	6
2.12.	Extension applications.....	7
2.13.	Other Post-Authorisation Activities	7
2.13.1.	Aucatzyl - Obecabtagene autoleucel - Orphan - EMA/R/0000319964	7
2.13.2.	Kymriah - Tisagenlecleucel - Orphan - EMA/PAM/0000258545.....	7
2.13.3.	Roctavian - Valoctogene Roxaparvovec – EMEA/H/C/005830.....	7
2.14.	Companion diagnostics - initial consultation	7
2.15.	Companion diagnostics – Follow-up consultation	7
3.	Certification of ATMPs	7
3.1.	Opinion.....	8
3.2.	Day 60 Evaluation Reports.....	8
3.3.	New Applications.....	8
4.	Scientific Recommendation on Classification of ATMPs	8
4.1.	New requests – Appointment of CAT Coordinator	8

4.1.1.	Recombinant chicken annexin V labelled inactivated autologous tumour cells	8
4.1.2.	Adenovirus type 5 vector expressing human granulocyte-macrophage colony-stimulating factor	8
4.1.3.	Autologous adipose-derived stromal vascular fraction	8
4.2.	Day 30 ATMP scientific recommendation	9
4.2.1.	Live attenuated viral vector vaccine based on SARS-COV-2 backbone, expressing human interferon beta	9
4.2.2.	Messenger ribonucleic acid (mRNA) molecules encoding a cytosine-to-thymine transcription activator like effector base editor (TALEB) targeting APOC3 gene	9
4.2.3.	Allogeneic CAR-T lymphocytes targeting CEACAM6	9
4.3.	Day 60 revised scientific recommendation (following list of questions)	9
4.4.	Finalisation of procedure	9
4.4.1.	Live attenuated Listeria monocytogenes bearing plasmids encoding the recombinant chimeric fusion protein of truncated nonhemolytic listerolysin O (tLLO) and a tumour associated antigen (TAA) comprised of two extracellular (EC1 and EC2) and one intracellular (IC1) fragments of the human Her2/neu protein	9
4.4.2.	Allogeneic umbilical cord-derived Mesenchymal stem cells	9
4.4.3.	Autologous chimeric antigen receptor T cells against epidermal growth factor variant III (EGFRvIII) and messenger ribonucleic acid vaccine lipoplexes encoding EGFRvIII (intracerebroventricular administration)	10
4.4.4.	Autologous chimeric antigen receptor T cells against epidermal growth factor variant III (EGFRvIII) and messenger ribonucleic acid vaccine lipoplexes encoding EGFRvIII (intravenous administration).....	10
4.4.5.	Extracellular vesicles from Wharton Jelly hTERT- expressing Mesenchymal Stromal Cells (MSCs) loaded with the micro-RNA miR-140	10
4.5.	Follow-up and guidance.....	10
5.	Scientific Advice	10
5.1.	New requests - appointment of CAT Rapporteurs	10
5.1.1.	Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers	10
5.1.2.	Scientific advice procedures starting at the next SAWP meeting	11
5.2.	Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs	11
5.3.	Finalisation of D70 procedures – feedback from the discussion meeting.....	11
5.4.	Final Advice Letters for procedures finalised the previous month.....	11
6.	Pre-Authorisation Activities	11
6.1.	Paediatric investigation plans.....	11
6.2.	ITF briefing meetings in the field of ATMPs	11
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	11
6.3.1.	Month 0 - Start of the procedure	11
6.3.2.	Month 1 – Discussion of eligibility	12
6.3.3.	Month 2 – Recommendation of eligibility.....	12
6.3.4.	Ongoing support.....	12

7.	Organisational, regulatory and methodological matters	12
7.1.	Mandate and organisation of the CAT	12
7.1.1.	CAT membership	12
7.1.2.	Nominated proxy	12
7.1.3.	CAT Strategic Review & Learning meeting (SRLM) under the Cypriot presidency	12
7.1.4.	Welcoming email to new members.....	12
7.2.	Coordination with EMA Scientific Committees	12
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	12
7.4.	Cooperation with the EU regulatory network	13
7.5.	Cooperation with international regulators	13
7.6.	CAT work plan	13
7.7.	Planning and reporting	13
7.7.1.	Revamp Project - report from the pilot project (pre-completion of reports by applicants)..	13
7.8.	Others	13
7.8.1.	Exploring ATMP feasibility assessment for surveillance capacity development	13
8.	Any other business	13
9.	Explanatory notes	14

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 18-20 March 2026. See March 2026 CAT minutes (to be published post April 2026 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 18-20 March 2026 meeting

1.3. Adoption of the minutes

CAT minutes for 18-20 February 2026 meeting

2. Evaluation of ATMPs

2.1. Opinions

2.1.1. Nadofaragene firadenovec - EMEA/H/C/005856

Treatment of adult patients with high-grade (HG), Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)

Scope: Opinion

Action: for adoption

List of outstanding issues adopted on 05.12.2025. List of questions adopted on 16.04.2025.

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Autologous melanoma-derived tumour infiltrating lymphocytes, ex vivo-expanded - EMEA/H/C/006563

Treatment of melanoma

Scope: Day 180 list of outstanding issues

Action: for adoption

List of questions adopted on 18.07.2025.

2.4. Day 120 list of questions

2.4.1. Zopapogene Imadenovec - Orphan - EMEA/H/C/006508

FGK Representative Service GmbH; Treatment of respiratory papillomatosis in adults

Scope: Day 120 list of questions

Action: for adoption

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Aucatzyl - Obecabtagene autoleucel - Orphan - EMA/VR/0000322591

Autolus GmbH

Rapporteur: Tineke van den Hoorn

Scope: Quality, opinion

Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Aucatzyl - Obecabtagene autoleucel - Orphan - EMA/R/0000319964

Autolus GmbH

Rapporteur: Tineke van den Hoorn, PRAC Rapporteur: Karin Erneholm

Scope: Renewal 1-year

Action: for adoption

2.13.2. Kymriah - Tisagenlecleucel - Orphan - EMA/PAM/0000258545

Novartis Europharm Limited

Rapporteur: Rune Kjekken, PRAC Rapporteur: Dirk Mentzer

Scope: PAM, PRAC lead procedure

Action: for adoption

2.13.3. Roctavian - Valoctogene Roxaparvovec – EMEA/H/C/005830

BioMarin International Limited

Rapporteur: Violaine Closson-Carella, Co-Rapporteur: Silke Dorner

Scope: Withdrawal of the marketing authorisation

Action: for information

Note: the MAH informed EMA of their intention to withdraw the MA for Roctavian

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to

contain commercially confidential information.

3.1. **Opinion**

No items

3.2. **Day 60 Evaluation Reports**

No items

3.3. **New Applications**

No items

4. **Scientific Recommendation on Classification of ATMPs**

4.1. **New requests – Appointment of CAT Coordinator**

4.1.1. Recombinant chicken annexin V labelled inactivated autologous tumour cells

Treatment of solid tumours, especially renal cell carcinoma and breast cancer

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

4.1.2. Adenovirus type 5 vector expressing human granulocyte-macrophage colony-stimulating factor

Treatment of bladder cancer

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

4.1.3. Autologous adipose-derived stromal vascular fraction

Treatment of acute spinal cord injury

Scope: ATMP scientific recommendation

Action: for nomination of CAT coordinator

4.2. Day 30 ATMP scientific recommendation

4.2.1. Live attenuated viral vector vaccine based on SARS-COV-2 backbone, expressing human interferon beta

COVID-19 prophylaxis

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. Messenger ribonucleic acid (mRNA) molecules encoding a cytosine-to-thymine transcription activator like effector base editor (TALEB) targeting APOC3 gene

Treatment of familial chylomicronaemia syndrome (FCS) and severe hypertriglyceridemia (sHTG)

Scope: ATMP scientific recommendation

Action: for adoption

4.2.3. Allogeneic CAR-T lymphocytes targeting CEACAM6

Treatment of pancreatic ductal adenocarcinoma (PDAC) surgery-eligible patients

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Live attenuated *Listeria monocytogenes* bearing plasmids encoding the recombinant chimeric fusion protein of truncated nonhemolytic listeriolysin O (tLLO) and a tumour associated antigen (TAA) comprised of two extracellular (EC1 and EC2) and one intracellular (IC1) fragments of the human Her2/neu protein

Treatment of pulmonary recurrence of resected osteosarcoma

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.4.2. Allogeneic umbilical cord-derived Mesenchymal stem cells

Treatment of lupus nephritis (LN) and systemic lupus erythematosus (SLE)

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.4.3. Autologous chimeric antigen receptor T cells against epidermal growth factor variant III (EGFRvIII) and messenger ribonucleic acid vaccine lipoplexes encoding EGFRvIII (intracerebroventricular administration)

Treatment of EGFRvIII-positive glioblastoma

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.4.4. Autologous chimeric antigen receptor T cells against epidermal growth factor variant III (EGFRvIII) and messenger ribonucleic acid vaccine lipoplexes encoding EGFRvIII (intravenous administration)

Treatment of EGFRvIII-positive glioblastoma

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.4.5. Extracellular vesicles from Wharton Jelly hTERT- expressing Mesenchymal Stromal Cells (MSCs) loaded with the micro-RNA miR-140

Treatment of osteoarthritis

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	09-12.03.2026
- Appointment of CAT Peer Reviewers:	18-20.03.2026
- SAWP first reports:	31.03.2026
- CAT Peer Reviewer comments (NC & C):	06.04.2026
- CAT Peer Reviewer comments (Q):	08.04.2026
- Discussion at SAWP:	07-10.04.2026

- Discussion at CAT and feedback to SAWP: 15-17.04.2026

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	07-10.04.2026
- Appointment of CAT Peer Reviewers:	15-17.04.2026
- SAWP first reports:	27.04.2026
- CAT Peer Reviewer comments (NC & C):	30.04.2026
- CAT Peer Reviewer comments (Q):	06.05.2026
- Discussion at SAWP:	04-07.05.2026
- Discussion at CAT and feedback to SAWP:	11-13.05.2026

No items

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	09-12.03.2026
SAWP recommendation:	10.04.2026
CAT recommendation:	17.04.2026
CHMP adoption of report and final recommendation:	23.04.2026

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. Nominated proxy

Action: for information

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Cypriot presidency

Scope: Preparation for the meeting

CAT: Rafaella Pontou

Action: for information

7.1.4. Welcoming email to new members

Action: for information

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

No items

7.6. CAT work plan

No items

7.7. Planning and reporting

7.7.1. Revamp Project - report from the pilot project (pre-completion of reports by applicants)

Scope: The Revamp Project, which has been focussing for the last 4 years on revamping the assessment report templates, carried out a pilot whereby applicants were asked to complete the factual parts of the D80 AR templates. 11 companies participated in the pilot and one of the products was an ATMP. Now that the pilot has concluded, the Revamp team would like to bring to the committees the findings and the recommendations from the Revamp Steering Group

Action: for information

7.8. Others

7.8.1. Exploring ATMP feasibility assessment for surveillance capacity development

Scope: Surveillance

EDQM: Christina Goengrich, Katarina Bacevic

Action: for discussion

8. Any other business

No items

Date of next CAT meeting:

15-17 April 2026

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

[Abbreviations in Committee CMD documents and in relation to EMA regulatory activities](#)

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

GMP and GCP Inspections Issues (section 2.10)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Companion diagnostics (section 2.14. & 2.15.)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT.

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested

parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/